Here’s why Telix’s (ASX: TLX) shares are up on ASX?
Key Takeaways:
Telix has been given FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment.
Telix has signed an exclusive deal with Xiel for the distribution of Illuccix® in the UK, Northern Ireland, and the Republic of Ireland.
Telix is forming a network of leading distribution partners to ensure a solid presence to improve its service to customer sites and bring its imaging agent to patients across the region.
On 29 March 2022, Telix Pharmaceuticals Limited (ASX: TLX) made two announcements. Post their release of announcements on ASX, the Company's shares moved up by 7.469% and were trading at AU$4.460 (AEDT 1:10 PM). In this article, we will look at these two announcements.
On 29 March 2022, Telix Pharmaceuticals Limited (ASX: TLX) made two announcements. Post their release of announcements on ASX, the Company's shares moved up by 7.469% and were trading at AU$4.460 (AEDT 1:10 PM). In this article, we will look at these two announcements.
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Here’s why Telix’s (ASX: TLX) shares are up on ASX?
Key Takeaways:
On 29 March 2022, Telix Pharmaceuticals Limited (ASX: TLX) made two announcements. Post their release of announcements on ASX, the Company's shares moved up by 7.469% and were trading at AU$4.460 (AEDT 1:10 PM). In this article, we will look at these two announcements.
On 29 March 2022, Telix Pharmaceuticals Limited (ASX: TLX) made two announcements. Post their release of announcements on ASX, the Company's shares moved up by 7.469% and were trading at AU$4.460 (AEDT 1:10 PM). In this article, we will look at these two announcements.
Recent Latest News